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Abstract 
The clinical success of B cell-depleting therapies in multiple sclerosis (MS) has identified an 
important, yet poorly understood pathogenic role for B cells in disease. An animal model of 
MS, experimental autoimmune encephalomyelitis (EAE), is typically induced through 
immunization with short myelin-derived peptides. B cells recognize whole proteins and not 
peptides, therefore their activation and involvement in peptide models of EAE is largely 
excluded. The goal of this study was to develop a novel fusion myelin protein reagent 
(MOGtag) to induce autoimmune responses in mice that incorporate T and B cell recognition 
of antigen. Characterization of the autoimmune response revealed the formation of a T cell-
dependent germinal center B cell response. Further, immunization with MOGtag resulted in a 
chronic disease with evidence of an ongoing immune response, and central nervous system 
pathology featuring T cell infiltration of white and gray matter as well as formation of 
meningeal B cell clusters.  
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Chapter 1  
1 Introduction and literature review 
1.1 Multiple sclerosis  
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) 
where host immune cells target myelin for destruction (1). Myelin is a fatty sheath 
produced by oligodendrocytes that surround and protect axons of nerve cells, and is 
essential for proper and rapid signal transduction (2-4). As the myelin is damaged, 
communication signals within the CNS, and consequently the rest of the body, are 
delayed and disrupted. This can lead to a wide range of symptoms and signs including 
fatigue, visual impairment, and motor and cognitive disabilities that may accumulate over 
time as the disease progresses (5).  
MS is one of the most common autoimmune diseases of the CNS (6, 7). It affects 2.5 
million people worldwide, with varied rates across different regions and populations (8). 
MS is particularly prevalent in Canada – affecting up to 350 in every 100, 000 Canadians 
(9). Separating by gender, MS is approximately two times more prevalent in females than 
males (10). MS is often referred to as a young adults’ disease because it generally 
develops in early adulthood between 20-40 years of age, although cases of earlier and 
later development have been reported (8, 11). It is reported that most MS patients will be 
unemployed within 15 years of its first diagnosis due to the steady decline in motor and 
cognitive functions (8). Further, the overall life expectancy within the MS population is 
5-10 years lower compared to the healthy, unaffected population (5).  
The disease course and prognosis of MS following its initial diagnosis is highly variable 
and unpredictable (1). Instead, MS is broadly categorized into four subtypes based on 
differences in clinical presentation and progression over time (12). The most common 
form, relapsing-remitting MS, is characterized by episodes of inflammatory attacks on 
the CNS followed by periods of remission. Most patients with relapsing-remitting MS 
eventually fall into the secondary progressive MS category, where there is little to no 
recovery and there is a gradual decline in cognitive and physical abilities (13). Primary 
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progressive and primary relapsing MS display steady accumulation of neurological 
disability over time (14). It is unclear whether the clinical variability within these 
categories actually reflect different pathogenic mechanisms. However, the characteristic 
CNS inflammation and demyelinating features present in all four MS subtypes suggests 
that there is a common etiology.  
At the moment, there are no cures or preventative measures for MS. Instead, available 
clinical therapies are intended only for individuals that have already been diagnosed with 
MS (further discussed in section 1.5.3 Available clinical therapies below). Taken 
together, MS is a chronic and debilitating disease in which we have little knowledge and 
control over its initial development and progression. As it stands, it remains a priority to 
identify the underlying cellular pathogenic mechanisms involved in the initiation and 
maintenance of disease, in hopes of developing more effective and targeted therapies for 
MS patients.  
1.2 Genetics in Multiple Sclerosis  
It is unclear how MS is first initiated in individuals. The etiology of MS remains 
complex, and it can be argued that there is not one single defining cause or factor that 
results in its initiation. Instead, it is now widely accepted that disease development is 
influenced through a combination of environmental and genetic factors (7). 
1.2.1 Familial genetic predisposition  
The idea that susceptibility to MS was in part influenced by genetics, and therefore could 
be inherited, was first proposed in the 1890s following the discovery of familial 
aggregation (15). Compared to the general population, families with a history of MS have 
an increased likelihood of developing the disease. Individuals with a first degree relative 
who has MS have a 15-25 fold greater risk in developing MS than the general population 
(15). Furthermore, the risk for offspring of parents with MS is significantly increased 
when both parents have MS, compared to only one parent (15-17). Adoption studies 
indicated that adopted relatives and non-related individuals raised in an MS household 
were at no greater risk in developing MS than the general population (15). Taken 
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together, the familial susceptibility in MS is due to inherited and shared genes within 
families with MS, and is likely less influenced by shared family environment.  
1.2.2 Immune-mediated genetic predisposition  
There has been an increase in effort over the past few decades to identify common 
genetic traits and alleles that confer susceptibility risk to MS. The presence of immune 
cells in MS pathology heavily suggested that immune-associated genes were involved. 
Indeed, genomic studies have confirmed that major histocompatibility complex (MHC) 
class II human leukocyte antigen (HLA) molecules are associated with MS, and that 
disease-associated variations of these molecules confer the greatest genetic risk to MS 
(15, 18, 19). MHC class II molecules are protein receptors expressed on the surface of 
antigen-presenting cells (APCs) and are essential for the activation of CD4+ T cells. In an 
autoimmune context, it may confer risk by facilitating self-antigen presentation to 
pathogenic CD4+ T cells (further discussed in section 1.4.Immunology of Multiple 
Sclerosis below). Amongst the MHC class II locus, the allelic variations associated with 
disease have so far been restricted to the HLA-DR and HLA-DQ loci, including the 
HLA-DRB1*1501 or DQB1*0602 alleles (20, 21). Specific MHC class I HLA 
molecules, which are involved in presenting intracellular antigens (Ags) to CD8+ T cells, 
have also been linked to confer risk or protection from MS, independently of MHC class 
II susceptibility (22-24).  
More recent genome-wide association studies of MS have identified additional groups of 
immune-related genes in close association with disease susceptibility. These include, but 
are not limited to, genes involved in cytokine (CXCR5, IL21B) and co-stimulation 
(CD40, CD80, CD86) signaling pathways (18, 25). Taken together, the majority of 
disease-associated alleles that have been identified thus far are centered on the immune 
system, therefore providing strong evidence that MS is largely a disorder of the immune 
system.  
1.3 Environmental Factors in Multiple Sclerosis 
Despite a strong genetic basis in MS, not all individuals with genetic risk go on to 
develop MS. Instead, a complex interplay of non-genetic related factors are implicated in 
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triggering disease manifestation. To date, a multitude of other factors have been 
suggested, including: environmental (infectious agents, sunlight) and lifestyle (diet, 
smoking) factors (26-28). In this section I will focus on two common environmental 
factors implicated in MS.  
1.3.1 Viral infections  
Infectious agents such as viruses are common environmental candidates for MS, in part 
due to their involvement with other autoimmune diseases (29, 30). In MS, potential 
viruses that are speculated to initiate disease have been narrowed down to those within 
the Herpesviridae family, including the Human Herpesvirus 6 and Epstein-Barr virus 
(EBV) (7, 26). This is based on reported findings of 1) presence of EBV 
deoxyribonucleic acid (DNA) in the CNS of some MS patients and 2) MS development is 
positively correlated with anti-EBV antibody (Ab) titer levels in the serum (31, 32). 
Several theories have been suggested to explain how viruses play a role in initiating MS.   
 
The first proposed mechanism is based on the concept of molecular mimicry, in which 
structural and sequence similarities shared between foreign- and self-antigens 
unintentionally direct immune cells to target the host (33-37). In support of this, T cells 
of some MS patients have been shown to cross-react with both EBV Ags and myelin-
derived Ags found in the CNS (32, 38).  
The second theory suggests an autoreactive B cell hypothesis. Under normal 
circumstances, the immune system has regulatory mechanisms to prevent immune cells 
from mounting an immune response against self-antigens (refer to 1.4.Immunology of 
Multiple Sclerosis section). In MS, it is believed that virally-infected autoreactive B cells 
are able to escape apoptosis through expression of viral genes that mimic survival signals 
(31, 39). This can lead to an accumulation of autoreactive B cells that can subsequently 
activate nearby autoreactive T cells in the CNS to propagate an autoimmune response.  
1.3.2 Sunlight exposure  
The lack of sunlight has also been implicated in influencing the development of MS (40). 
Individuals located further from the equator are at a significantly greater risk for 
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developing MS than those in close proximity to the equator (7, 27, 41). More 
interestingly, geographical distribution specifically during early adolescence (0-15 years 
of age) is reported to influence the risk of disease (7). Migration studies reported that 
individuals who migrate from either low-to-high or high-to-low risk environments are 
likely to acquire the environmental risk of the new region. In contrast, individuals that 
migrate post-adolescence retain the environmental risk of their former geographic area 
(7). The reduced risk of MS in regions of greater sun exposure and with the use of 
vitamin D supplements suggests a protective role for vitamin D (42). Vitamin D linkage 
to factors associated with immune regulation is currently being investigated in animal 
models of MS.  
1.4 Immunology of Multiple Sclerosis 
The immune system plays an essential role in targeting invading foreign pathogens for 
destruction. To prevent the immune system from targeting its own cells, there are 
regulatory checkpoints to limit the generation of potential autoreactive cells (central 
tolerance) and to prevent their activation in the periphery (peripheral tolerance). 
Autoimmune diseases reflect a failure in immune regulation at these checkpoints.  
1.4.1 Immune response against foreign antigens 
Immune responses are initiated in secondary lymphoid organs (SLOs) such as lymph 
nodes (LNs) (Figure 1). LNs are immune structures consisting mainly of B and T 
lymphocytes in organized compartments referred to as B cell follicles and T cell zones 
within the lymphoid cortex, respectively (43). Tissue-derived Ags and foreign Ags 
present in the lymph enter LNs via afferent vessels (44). Immature dendritic cells that 
sample local tissue Ags also migrate via lymph to the LN and function as APCs upon 
maturation (45-47). APCs, such as dendritic cells, macrophages and B cells, are a group 
of cells with a specialized ability to internalize Ag for processing and loading of 
processed peptides onto their MHC II molecules for the activation of T cells (48, 49). 
Successful activation of T cells generally requires two signaling events. The first signal, 
as described above, involves T cell receptor (TCR) recognition and binding of an 
appropriate epitope or “peptide” Ag that is presented on surface MHC molecules of  
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Figure 1: Immune responses are initiated in secondary lymphoid organs. Tissue-
derived and soluble antigens found in lymph circulation enter lymph nodes via afferent 
lymphatics. Dendritic cells (DC) take up, process, and present antigens on their MHC II 
molecules to activate nearby T cells in the T cell zone. Activation of B cells occurs in the 
B cell zone upon binding of antigen to the B cell receptor. Newly activated B and T cells 
can relocate to the interfollicular zone and form interactions that will determine their fate 
commitment. B cells can either commit to the extrafollicular pathway to differentiate into 
short-lived plasmablasts, or commit to the germinal center pathway and enter the follicle. 
In case of the latter, T cells in the interfollicular zone commit to Tfh differentiation to 
participate in the germinal center response. B cells participating in the germinal center 
response undergo affinity maturation, somatic hypermutation and isotype switching. 
Long-lived, high-affinity memory B cells and antibody-secreting plasma cells are 
generated from the germinal response. 
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APCs (50). The second signal involves binding of costimulatory ligands and receptors 
expressed on APCs and T cells, respectively.  
Unlike T cells, B cells are not dependent on MHC II Ag presentation and can bind 
directly to the Ag. The type of B cell response that is elicited depends on the Ag and its 
requirement for T cell help in generating an Ab response. Furthermore, B cells can also 
be potent APCs similar to dendritic cells, with the exception that Ag internalization is 
mediated through binding of the antigen-specific B cell receptor (BCR) (51). Ags taken 
up by the BCR are processed into short peptides and loaded onto MHC II molecules for 
presentation to T cells. Consequently, this results in B and T cell interactions where both 
cells are specific for the same Ag. Immune responses that incorporate B and T cell 
recognition of the same Ag results in the initiation of a germinal center (GC) response 
(52-54). GCs are highly specialized microenvironments within B cell follicles of SLOs. 
During this response, B cells undergo extensive clonal expansion, somatic hypermutation 
and isotype-switching (55). The end product is the generation of high-affinity plasma 
cells (PCs) or resting memory B cells that contribute to the long-lived humoral immune 
repertoire (56). Of particular interest are Ag-experienced memory B cells, which are 
capable of differentiating into PCs or initiating a germinal center response upon re-
exposure to the Ag (57). Additionally, memory B cells can be highly effective APCs and 
can stimulate or reactivate autoreactive T cells to facilitate an autoimmune response (57). 
Indeed, these T-cell dependent GC responses are thought to produce pathogenic B cell 
subsets that may participate in the MS immune response.  
Upon activation, antigen-experienced immune cells exit the SLO and home specifically 
to the site of inflammation. This process of leukocyte extravasation from the original site 
of activation to the inflamed region proceeds in a step-wise fashion involving a 
combination of adhesion molecules and chemokines. First, circulating leukocytes can 
tether to the endothelial membrane through the binding of selectins (58, 59). This 
interaction serves as the initial membrane attachment and tethering, and mediates 
leukocyte rolling in the direction of flow (60). Under normal non-inflammatory 
circumstances, rolling leukocytes form weak adhesion interactions through low-affinity 
integrins. However under inflammatory conditions, inflammatory chemokines help to 
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stabilize firm leukocyte:endothelium adhesion by increasing the receptor affinity of 
integrins. Consequently, the firmly adhered leukocyte becomes arrested at a single 
location and then proceeds with diapedesis into the tissue. 
1.4.2 Immune response in Multiple Sclerosis 
Similar to the immune response described above, the local CNS immune response in MS 
is speculated to be a reactivation of infiltrating antigen-experienced cells that were likely 
primed earlier in the periphery (61). While it has not been explicitly confirmed, previous 
and more recent studies suggest that CNS-draining cervical lymph nodes are the initial 
site of activation and maturation of immune cells involved in MS (61-64). Activation of 
T cells is an essential event in the early development of the autoimmune response in MS 
(65). Peripheral activation of autoreactive T cells may occur in the cervical LNs or in the 
circulation through direct encounter of degraded myelin fragments (62). Upon activation, 
autoreactive myelin-specific T cells home to the CNS where there is an abundance of 
processed myelin Ags being presented by local APCs (66, 67). Consequently, this leads 
to a cascade of inflammatory signaling events involving local activation and further 
recruitment of peripheral immune cells, thereby driving chronic progression of the 
disease response. Under non-inflammatory conditions, T cell entry into the healthy CNS 
is dependent on α4-integrin (68). In MS, enhanced T cell recruitment to the inflamed 
CNS is reported to involve an additional adhesion molecule known as P-selectin (69). 
Identification of specific adhesion molecules involved in immune cell recruitment during 
inflammation has led to the development of successful clinical therapies used today. 
Natalizumab, a monoclonal Ab targeted against α4-integrin, has been demonstrated to 
reduce clinical relapses in both animal models of MS and human MS by blocking T cell 
recruitment (70-72). In contrast, little is known regarding the recruitment mechanisms of 
B cells into the healthy and inflamed CNS. 
1.5 Pathology of Multiple Sclerosis 
1.5.1 Diagnosis and clinical monitoring  
The heterogeneous and complex nature of MS makes it difficult for an immediate 
diagnosis. According to McDonald’s criteria, the clinical definition of MS is defined by 
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episodes of neurological symptoms and disability caused by inflammatory attacks on the 
CNS that is disseminated over space and time (73-76). Magnetic resonance imaging 
(MRI) has become a central component in the clinical diagnosis and monitoring of MS 
owing to its sensitive ability in detecting white matter lesions (77, 78). Conventional MRI 
techniques can distinguish between older and “active” inflammatory lesions, and also 
quantify total lesion burden (79). Disease severity in MS is measured with the Expanded 
Disability Status Scale (EDSS), a 10-point rating scale that assesses clinical signs of 
neurocognitive and physical disability (80). The EDSS provides a general indication of 
the affected CNS areas and accumulation of disability over time. Together, MRIs and the 
EDSS are used to identify the clinical MS subtype (discussed above in section 1.1 
Multiple Sclerosis). Active lesions in conjunction with worsened clinical presentation 
reflect a “relapse”, whereas clinical worsening in the absence of new or currently active 
lesions often reflects “progression”. 
1.5.2 White and gray matter pathology 
Pathologically, MS is characterized by inflammatory immune cell infiltrates in close 
association with demyelinated regions throughout the brain and spinal cord (5).  Areas of 
demyelination, more commonly referred to as lesions, or “plaques”, can vary drastically 
in the size, the extent of myelin damage and repair in the surrounding area, and the 
cellular infiltrate composition (81). MS plaques likely reflect repeated inflammatory 
attacks, resulting in substantial axonal damage, loss of oligodendrocytes and eventually a 
scar-like appearance (5). Lesions commonly affect CNS white matter, however more 
recent histopathological analyses found evidence of gray matter pathology (82). By 
comparison, gray matter lesions had fewer immune cell infiltrates, suggestive of less 
inflammation (83). While gray matter pathology is most often seen in chronic MS, further 
studies are required to understand its implication in disease.  
The composition of inflammatory cell infiltrates in MS is diverse between patients, 
mainly comprising activated microglia (a type of resident cell in the CNS), macrophages 
and B and T lymphocytes in surrounding areas of demyelination (84, 85). T lymphocytes, 
predominantly CD8 and to a lesser extent CD4 T cells, are found in human MS lesions 
(86-88). Aggregates or clusters of B cells are found in the CNS meninges of MS patients 
10 
 
(89, 90). B cell clusters vary in size, ranging from diffuse numbers of B cells to more 
densely organized structures resembling ectopic follicle-like structures. Memory B cells, 
PCs, and actively proliferating B cells, suggestive of GC B cells, have been identified in 
B cell clusters (90, 91). Further, PCs and their secreted Ab products are also detected in 
the cerebrospinal fluid (CSF) of MS patients. Compared to healthy individuals, almost all 
MS patients have similar IgG Ab patterns in the CSF, referred to as “oligoclonal bands” 
(92, 93). At the moment, Ag specificity of the autoimmune response in MS remains 
largely unresolved. Based on demyelinating hallmarks in MS, myelin-derived Ags have 
been implicated and investigated, but with conflicting results. In support of this, both 
myelin-reactive B and T cells, and Abs have been detected in lesions and CSF in a subset 
of MS patients (94-97). This finding was not universal across all MS patients, and in 
some cases was also detected in healthy controls (98, 99). Moreover, anti-myelin Abs 
have been mostly reported in pediatric MS patients (100), whereas these Abs were either 
rare or no longer detectable in adult MS. Further investigation is necessary to determine 
the pathogenic contribution of myelin-reactive cells in MS.   
1.5.3 Available clinical therapies  
Currently available disease-modifying therapies, classified as first- or second-line, have 
been demonstrated to reduce the number of clinical relapses and delay accumulation of 
neurological disabilities in relapsing MS (101). At the moment, there are few clinically 
effective treatments for patients with progressive MS (101). First-line therapies are 
general immune modifiers intended to suppress the pro-inflammatory immune response 
(101). Second-line therapies such as Natalizumab are cell-targeted and function to inhibit 
immune cell entry into the inflamed CNS. More recently, a B cell-depleting second-line 
therapy known as Rituximab showed surprising therapeutic success, considering our 
understanding of B cell involvement in an animal model of CNS autoimmunity (further 
discussed in section 1.6 Animal models of Multiple Sclerosis below) (102). Rituximab is a 
monoclonal Ab directed against the CD20 transmembrane protein expressed on B cells. 
CD20 expression is present on pre-B cells and mature B cells, but lost upon 
differentiation into antibody-secreting cells (103, 104). Taken together, CD20+ non-
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antibody-secreting B cells play an important, yet poorly understood role in the 
pathogenesis and progression of disease.   
1.6 Animal models of Multiple Sclerosis 
Our current understanding of human MS is mainly attributed to the collaboration of 
multidisciplinary studies ranging from genome-wide analyses of individual genes to more 
broad-scale population-based studies. While providing excellent qualitative data, the 
nature of these studies provides little to no insight on the actual cellular mechanisms 
underlying MS pathology. Instead, we are restricted to spinal taps and blood samples, and 
in rare cases biopsies or post-mortem autopsies to uncover the cellular intricacies behind 
its pathology. These do not provide an adequate nor thorough examination of the 
underlying pathology over the course of the disease. As such, experimental animal 
models have become an essential and integral component of human disease research by 
allowing researchers to tackle the disease from various different aspects and at different 
disease stages. 
1.6.1 Experimental Autoimmune Encephalomyelitis 
The most widely used animal model in MS research is experimental autoimmune 
encephalomyelitis (EAE). EAE is an experimental model with CNS inflammation and 
demyelination hallmarks characteristic of human CNS autoimmunity (61). EAE has now 
been adapted for use in a wide range of species and can be induced through various 
means, including viral and chemical agents (105). One of the most common induction 
method of EAE is through direct immunization with a myelin-derived Ag (106). In mice, 
EAE is typically induced through immunization with short myelin peptides mimicking 
dominant CD4+ T cell epitopes. Peptide-induced models of EAE reflect a simplified 
version of a normally complex immune response, where activation of myelin-specific T 
cells represents the minimal requirement necessary for initiating disease (further 
described below). Alternatively, EAE could also be initiated passively through the 
adoptive transfer of previously activated myelin-specific CD4+ T cells (107). Immunized 
animals typically develop clinical signs of disease around 10-14 days post-immunization, 
and are scored on a standard EAE scoring system beginning with muscle loss in the tail 
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and continuing with ascending paralysis in the hind and front limbs. Inflammation and 
disease pathology of most rodent models of EAE are predominantly located within the 
spinal cord, which is in contrast to human MS where inflammatory lesions are commonly 
associated with the brain (61). 
EAE first started as an accidental discovery when a proportion of rabies vaccination 
patients receiving crude CNS extracts from infected rabbits developed acute episodes of 
paralysis (108). Eventually, it was confirmed that the muscle paralysis and encephalitis 
was actually a stereotypic immune response against the myelin components within the 
CNS (108). More systematic approaches of extraction and purification of individual 
myelin components identified myelin basic protein (MBP), proteolipid protein (PLP) and 
myelin oligodendrocyte glycoprotein (MOG) among the several encephalitogenic targets 
in this CNS-restricted immune response. In light of T cell biology advancements at the 
time, the EAE field shifted its focus to identifying the immunodominant T cell epitopes 
on myelin proteins that appropriately bound the MHC II/TCR complex. Myelin-derived 
peptides such as MOG35-55 that are analogous to the immunodominant epitopes were 
demonstrated to elicit an encephalitogenic immune response (109, 110). Combined with 
the relatively inexpensive cost and ease of synthesis, these short myelin peptides are now 
the most common form of Ag used today in EAE studies.  
By comparison, EAE models induced with whole protein Ags generate a more complex 
immune response by incorporating responses from other immune cells. MOG has 
emerged as a leading myelin autoantigen due to the presence of anti-MOG Abs and 
MOG-specific T cells in MS patients (111, 112). Further, immunization with whole 
MOG, but not MBP or PLP, has been demonstrated to initiate both a demyelinating 
autoantibody response and an encephalitogenic T cell response in rodents and marmosets, 
thereby producing an inflammatory CNS disease with demyelinating lesions 
characteristic of human MS (109, 113-117). MOG is expressed on the outermost lamellae 
of the myelin sheath and has been characterized as a type I integral membrane protein 
with a single extracellular Ig variable domain at the N-terminus (118). In particular, the 
extracellular domain of MOG, analogous to MOG1-125, has been identified as the 
encephalitogenic portion that is recognized by immune cells, and also contains the 
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immunodominant MOG35-55 peptide sequence recognized by CD4+ T cells (113). At the 
moment, rat, mouse and human-based versions of the MOG1-125 protein immunogen have 
been produced (discussed further).  
More recent to the EAE field are “spontaneous” models where genetically susceptible 
mice, in combination with environmental factors, can develop disease spontaneously – a 
scenario that better reflects human MS. In the majority of these spontaneous models, 
lymphocyte receptors are genetically modified to be myelin reactive, resulting in 
enhanced proportion of myelin-reactive cells that is sufficient to overcome immune 
tolerance. Other models of spontaneous EAE based on a modified cytokine profile have 
also been reported (119). To date, two spontaneous EAE models with known B cell 
involvement have been described (120-122). In one model, 2D2 mice (123) bearing 
TCRs specific for MOG35-55 are crossbred with IgHMOG mice (124) expressing BCRs 
specific for MOG1-125 to generate a double mutant mouse with genetically modified B 
and T cell receptors that can recognize the MOG autoantigen (120, 121). The single 
transgenic 2D2 mouse strain develops EAE at very low incidences (120, 121). However 
disease incidence increases greatly when combined with genetically modified MOG-
specific B cells (120, 121). Therefore the development of EAE in this model is largely B 
cell-dependent. The difficulty and unpredictability in disease manifestation in 
spontaneous EAE models remains one of the greatest challenges in preventing its wider 
adoption in the EAE field. Taken together, spontaneous models, while recapitulating 
many aspects of human MS, are a far more difficult and expensive alternative compared 
to induced models of EAE. 
1.6.2 Lessons learned from EAE: good and bad 
Since its first discovery, EAE has contributed greatly to our understanding of CNS 
autoimmunity, and has led to the development of clinical therapies used today. Recent 
clinical success of B cell-depleting therapies in MS revealed an important, but poorly 
understood pathogenic role of B cells in disease. This finding was unexpected based on 
experimental findings from earlier studies on the role of B cells in EAE. Induction of 
EAE is mainly dependent on CD4+ T cells, with little to no requirement for B cell 
involvement. Indeed, several groups have demonstrated that EAE can be induced in B 
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cell-deficient mice (125, 126). With the exception of mice immunized with a protein Ag 
based on human MOG (127-130), neither short-peptide nor protein-induced EAE is 
absolutely dependent on the presence of B cells as measured by the development of 
typical signs of disease (125, 130, 131). While protein-induced models of EAE that 
incorporate B cell involvement have been examined, these studies almost exclusively 
looked at the Ab response which, based on the therapeutic mechanism of Rituximab is 
not the main contributors to disease. Instead, B cells derived from the GC response have 
been implicated (62, 132). Collectively, these findings indicate a need to reevaluate the 
appropriateness of peptide-induced models of EAE to investigate the role of B cells in 
pathology. 
There are two conceptual reasons why peptide-induced EAE models cannot model a 
more complex pathogenic immune response incorporating both B and T cell recognition 
of an autoantigen. As discussed earlier (refer to section 1.4 Immunology of Multiple 
Sclerosis), B cells often rely on conformational epitopes of whole proteins, and therefore 
short linear myelin peptides mimicking dominant CD4+ T cell epitopes are not accessible. 
Further, peptides can be loaded directly onto the MHC II/TCR Ag complex, thus 
bypassing the BCR-mediated Ag uptake and processing for presentation to cognate T 
cells. This short-circuits the Ag specificity of the interactions with T cells and affects the 
competition for Ag binding between somatically mutated B cells that is inherent to the 
maturation of the GC response (133).  
The primary factors limiting the use of larger protein Ags to induce EAE that 
incorporates more than just CD4+ T cell recognition of the autoantigen is the relative cost 
and difficulty of obtaining or producing them. Few commercial sources exist, and 
available expression vectors for in-house production are based on inefficient and out-of-
date expression systems. Further, purification protocols are complex, laborious, and often 
depend on specialized equipment (109), complicated in part by the insolubility of the 
MOG protein itself. It is also important to note that all expression systems that we have 
identified produce fusion proteins consisting of the MOG extracellular domain, various 
purification tags, and often additional sequences that we cannot identify. Most 
incorporate either human or rat MOG1-125 (134), and therefore when used in mice 
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represent a cross-reactive response not ideal for some investigations of autoimmune-
specific cell interactions.  
1.7 Thesis hypothesis and objectives 
MS is a complex autoimmune disease characterized by heterogeneous CNS pathology 
involving many immune cells. Although the EAE model has contributed significantly to 
advancing our knowledge of CNS inflammation, peptide Ag models of EAE have 
inevitably shortsighted our understanding of the complex immune response in MS. There 
is an urgent need to revisit the experimental model to address these limitations. Ideally, 
short myelin peptides commonly used for EAE should be replaced with whole myelin 
protein Ags that incorporate other immune cells known to contribute to disease. The few 
available myelin protein Ags are expensive and difficult to produce, and are often based 
on a foreign species thereby generating a cross-reactive autoimmune response. Therefore 
the goal of this thesis is to develop a mouse-based myelin protein Ag using simple and 
inexpensive laboratory equipment to facilitate its wider availability and usage in the EAE 
field.  
Hypothesis: 
We hypothesize that EAE induced through immunization with a myelin protein Ag will 
initiate a more complex autoimmune CNS disease that incorporates B cell responses.  
Research Objectives: 
1) To develop a mouse-based myelin protein Ag for the induction of an autoimmune 
response in mice that incorporates B and T cell recognition of the Ag  
2) To characterize the GC response and autoimmune CNS pathology induced by the 
mouse-based myelin protein 
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Chapter 2  
2 Materials and Methods 
2.1 Mice 
C57Bl/6 and 2D2 TCR transgenic (123) mice were purchased from Jackson Laboratories. 
B1-8 mice (135) with a homozygous deletion of the Jκ locus (136) were a generous gift 
from Dr. Ann  Haberman. IgHMOG MOG-specific BCR knockin mice (124) were received 
as a gift from Hartmut Wekerle. Mice were housed in a specific pathogen-free barrier at 
West Valley Barrier. Animal protocols (#2011-047) were approved by the Western 
University Animal Use Subcommittee. 
2.2 Antibodies for flow cytometry and histology 
The following antibodies were purchased from BD Biosciences: anti-CD4-V450 (RM4-
5), anti-CD45R-V450 (RA3-6B2), anti-CD138-BV421 (281-2), anti-CD19-BV711 
(1D3), anti-CD95-PE-Cy7 (Jo2), anti-Bcl6-A647 (K112-91), anti-CD4-A647 (RM4-5), 
anti-IgG1-APC (A85-1), and anti-CD62L-A700 (MEL-14). The following antibodies 
were purchased from BioLegend: anti-IgKappa-Biotin (RMK-12), anti-IgLambda-Biotin 
(RML-42), and anti-His Tag-purified (J099B12). The following antibodies were 
purchased from eBioscience: anti-IgD-eF450 (11-26), anti-CD3-FITC (145-SC11), anti-
CD38-PE (90), anti-CD4-PE-Cy5 (RM4-5), anti-IgM-PE-Cy5 (II/41), anti-CD279-Biotin 
(RMP1-30), and Streptavidin-eF780. FluoroMyelin Red for myelin staining was 
purchased from Invitrogen. 
2.3 Recombinant mouse MOGtag  
2.3.1 Vector design 
The MOGtag insert was designed using SnapGene software to include the following: a 
tobacco etch virus (TEV) cleavage sequence site (ENLYFQ/G), the extracellular 
immunoglobulin domain of mouse MOG (residues 1-125), a TAA stop codon and BglII 
and EcoRI restriction sites added to the 5’ and 3’ ends, respectively. MOGtag insert 
sequence was codon optimized for expression in Escherichia coli and synthesis in the 
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pQE-12 vector by Celtek Genes. The insert was then cloned into the pET-32a(+) vector 
containing the gene for thioredoxin (Novagen) and then transformed into BL21 E. coli 
using standard transformation procedures.  
2.3.2 Protein expression and purification 
A protocol for purification of MOGtag protein was adapted from previous systems (109). 
pET-32a(+) MOGtag BL21 E. coli was cultured in LB medium at 37°C to an O.D. of 0.6, 
when protein expression was induced overnight with 1 mM Isopropyl β–D-1-
Thiogalactopyranoside (IPTG). Bacterial cells were pelleted and resuspended in lysis 
buffer (0.1 mg/mL hen egg lysozyme, 0.1% Triton-X (v/v) in PBS) then lysed to collect 
inclusion bodies. The inclusion body pellet was resuspended in 500 mM NaCl, 20 mM 
Tris-HCl, 5 mM imidazole, pH 7.9 (Buffer A) and incubated at 4°C, then denatured with 
the addition of 6 M guanidine (Buffer B). The protein suspension was centrifuged at 4°C 
to collect the supernatant containing the solubilized proteins.  Before protein absorption, 
His-Bind nickel resin (Novagen) was prepared according to the manufacturer’s 
instructions. Briefly, the nickel resin was washed and treated with distilled water and 200 
mM NiSO4, then equilibrated with Buffer B. The solubilized proteins containing MOGtag 
was incubated with the charged nickel resin in a standard 50 mL centrifuge tube at 4°C. 
Following centrifugation, the supernatant was kept for further rounds of purification and 
MOGtag was eluted from the pelleted resin with 500 mM imidazole, 500 mM NaCl, 20 
mM Tris-HCl, and 6 M guanidine. Elutions were pooled and exchanged by overnight 
dialysis at 4°C into the storage buffer containing 0.115% glacial acetic acid, 3 mM 
sodium acetate and concentrated with PEG 3350 and PEG 8000 (BioShop) to 5 mg/mL 
before storage at -20°C. Protein expression and quantification were confirmed using 
standard SDS-PAGE (Bio-Rad) and Bradford Assay kits (Bio-Rad) according to the 
manufacturer’s instructions. 
2.3.3 TEV protease cleavage of MOGtag protein 
Purified MOGtag was dialyzed into 50 mM Tris-HCl, 0.5 mM EDTA and 5 mM BME. 
TEV protease enzyme (137) (a generous gift from Dr. John McCormick (138)) was added 
at a 1:20 (mg/mg) ratio TEV to MOGtag protein and left at 4°C for two days before 
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removal of the vector Histag from the cut MOG1-125 using nickel resin purification as 
described above. Purified MOG1-125 was dialyzed into the storage buffer as described 
above and concentrated to 2.24 mg/mL before storage at -20°C.  
2.3.4 MOGtag Alexa Fluor 647 fluorophore conjugation 
Direct conjugation of MOGtag to Alexa Fluor 647 was performed using the NHS Ester 
and C2 Maleimide fluorophore labeling kits (Life Technologies) according to the 
manufacturer’s instructions. 
2.4 Adoptive transfer and immunization 
Naïve antigen-specific T and B cells were isolated from red fluorescent (RFP+) 2D2 and 
green fluorescent (GFP+) IgHMOG mice, respectively, as previously described (139), and 
transferred into wild type C57Bl/6 recipients. Briefly, LNs and spleens of RFP+ 2D2 and 
GFP+ IgHMOG mice were dissociated and T and B cells were isolated using EasySep 
Negative selection Mouse T and B cell Enrichment Kits (StemCell Technologies). Unless 
otherwise stated, 5 x 105 T cells and 5 x 106 B cells per mouse were transferred 2 days 
prior to immunization. To induce a GC response, mice were immunized in the footpad 
with 125 µg MOGtag in Complete Freund’s Adjuvant (CFA) (Sigma-Aldrich). Draining 
popliteal LNs were harvested at the indicated timepoints for analysis. 
2.5 Induction of experimental autoimmune 
encephalomyelitis 
6-8 week old C57Bl/6 mice were immunized s.c. on day 0 at two sites at the base of the 
tail with either 0.5 mg of MOGtag, 0.224 mg of MOG1-125, or 0.04 mg of commercially-
synthesized MOG35-55 (Tocris) in CFA. At the same time mice were also administered 
250 ng of pertussis toxin (PTX) (List Biological Laboratories) i.p. and, when indicated, 
again on day 2. Clinical disease was monitored daily and was scored as follows: 0) no 
clinical signs; 1) tail paralysis; 2) tail paralysis and hind limb weakness; 3) hind limb 
paralysis; and 4) complete hind limb paralysis and front limb weakness. Half points were 
given for intermediate scores.  
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2.6 Flow cytometry 
Draining inguinal LNs were harvested from mice at the study endpoint and were prepared 
as previously described (139). Briefly, LN cell suspensions were blocked with an anti-Fc-
γ receptor (CD16/32 2.4G2) in PBS containing 1% FBS before further incubation with a 
combination of the Abs mentioned above in section 2.2 Antibodies for flow cytometry and 
histology). Dead cells were excluded by staining with the Fixable Viability Dye 
eFluor506 (eBioscience). Flow cytometry was performed on a LSRII cytometer (BD 
Immunocytometry Systems) and analyzed with FlowJo software (Treestar). 
2.7 Immunofluorescent histology 
At the end of the experiment or earlier, if the mouse reached a predetermined endpoint, 
spinal cords were extracted from mice and prepared as previously described (139). 
Briefly, 5-9 evenly spaced spinal cord tissues spanning the lumbar to cervical regions 
were cut and frozen in OCT (TissueTek) media. Serial cryostat sections (7 µm) were 
blocked in PBS containing 1% Bovine Serum Albumin, 0.1% Tween-20 and 10% rat 
serum before proceeding with staining. Sections were mounted with ProLong Gold 
Antifade Reagent (Invitrogen) and stored at -20°C. Tiled images of whole spinal cord 
sections (20x) were imaged using DM5500B fluorescence microscope (Leica).  
2.8 Image and statistical analyses 
Histology images were analyzed by a blinded reviewer based on the number of B cell 
clusters and for the presence and localization of CD4+ T cell infiltration.  
PRISM software was used to analyze FACs and histology data. Unless otherwise stated, 
T-tests were used for single comparisons, and ANOVA followed by either a Bonferroni 
or Tukey’s post-hoc test were used for comparison between multiple groups. For all 
experiments: *p<0.05, **p<0.01 and ***p<0.001 were considered significant.   
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Chapter 3  
3 Results 
3.1 Design of the mouse MOG1-125 thioredoxin tag 
expression vector 
To develop an improved expression system for the production of large quantities of 
murine MOG extracellular domain, we began with the mouse sequence for MOG1-125 
(GenBank NM_010814.2), and linked the 5’end to a sequence generating a TEV protease 
cleavage site (Figure 2). An alternate form of the consensus cleavage site (ENLYFQ/G) 
(140) results in cleavage between the final glutamine and glycine, glycine being the first 
amino acid of MOG1-125. Therefore, TEV protease cleavage results in the removal of 
additional tag sequences, leaving pure MOG1-125 extracellular domain without any 
residual amino acids. This sequence was then codon optimized for efficient expression in 
bacteria resulting in changes in the DNA but not translated protein (Figure 2). The 
synthesized sequence was cloned into the pET-32a(+) expression vector and transformed 
into BL21 E. coli cells for efficient generation of a fusion protein consisting of the mouse 
MOG extracellular domain, purification tags including a 6xHis tag and an S-Tag, and 
finally thioredoxin to counteract the known insolubility of MOG itself (141).  
3.2 Generation and purification of the mouse MOG1-125 
thioredoxin tag expression vector 
While some purification protocols for current MOG expression systems require 
specialized equipment, such as HPLC (109), we developed an isolation protocol using 
only standard equipment available to the majority of immunology groups (see Material 
and Methods for detailed protocol). MOGtag protein expression in BL21 E. coli was 
induced by overnight culture with IPTG (Figure 3A). Inclusion bodies containing MOGtag 
were isolated from lysed bacterial cells via centrifugation and protein was denatured in 6 
M guanidine prior to absorption onto nickel resin in a standard 50 mL centrifuge tube. 
Following centrifugation, the supernatant was kept for further rounds of purification, 
while pure MOGtag was eluted from the pelleted resin with imidazole. Due to the very  
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Figure 2: Generation of the MOGtag fusion protein. Linear structure depicting the 
MOGtag fusion protein, along with the amino acid and DNA sequences. The mouse DNA 
sequence for MOG1-125 (in blue) and codon-optimized sequences (in black) are shown. 
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Figure 3: Production and purification of MOGtag fusion protein. (A) MOGtag 
purification from bacterial culture. Expression was induced in BL21 E. coli. by overnight 
culture with IPTG (T0 vs. Ti  (BL21 E. coli. induced with IPTG)). MOGtag protein was 
then purified from bacterial lysates (Lys.) through repeated absorption on nickel resin and 
elution of pure protein (Elutions 1-4). Some MOGtag protein remained following four 
rounds of absorption (Final Sup.), demonstrating that additional purification rounds could 
have yielded more protein. (B) TEV protease cleavage to remove the tag containing 
thioredoxin and purification sequences was performed after protein refolding. MOGtag 
was incubated with TEV protease (+ TEV Pro.). Absorption on nickel resin was used to 
remove uncut MOGtag and cut tag (Elution), leaving pure MOG1-125 (Sup.). 
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large amount of protein generated from the T7 expression system, 4-6 rounds of 
absorption were required. Resulting elutions were subsequently pooled. Greater than 250 
mg of protein was obtained from an initial 2 L of bacterial culture. Protein was refolded 
through dialyzation to acetate buffer and concentrated to 5 mg/mL. Pure MOG1-125 was 
generated from MOGtag by cleavage with TEV protease and removal of cut tag (Figure 
3B). Taken together, MOGtag is easily purified in large quantities and, to our knowledge 
is the only system that allows for the production of pure MOG protein without additional 
foreign tag sequences. 
3.3 MOG-specific B cells recognize MOGtag 
An important precondition for the use of MOGtag to induce an appropriate anti-MOG 
protein B cell response is that it must be recognized by MOG-specific B cells. IgHMOG 
mice possess a BCR variable region derived from a MOG-specific hybridoma inserted 
into the endogenous locus. This greatly increases the number of MOG-specific B cells 
(124), presumably dependent on heavy chain pairing with an appropriate light chain. 
Further, IgHMOG cells have been confirmed to be pathogenic as spontaneous CNS 
autoimmune disease develops with high incidence in the progeny of these mice crossed 
with mice bearing a transgenic TCR for MOG35-55 (120, 121). 
In preliminary experiments, LN cells from wild type C57Bl/6 mice and IgHMOG mice 
were incubated with MOGtag followed by anti-His tag secondary and fluorescently-
labeled anti-IgG1 tertiary Abs. FACS analysis revealed little MOGtag binding by C57Bl/6 
cells as expected, due to the extremely low numbers of antigen-specific cells in naïve 
mice. In contrast, ~15% of B cells from IgHMOG mice, but not other lymphocytes, bound 
MOGtag (Figure 4A). This confirms that B cells with known specificity for MOG protein 
appropriately recognize MOGtag. It also demonstrates the utility of MOGtag to identify 
MOG-specific B cells by FACS. To facilitate this, we directly conjugated MOGtag to the 
fluorophore Alexa Fluor 647. Both amine- and thiol-reactive approaches were tested and 
the amine-reactive NHS ester was found to produce the best cell labeling (Figure 4B). 
MOGtag-A647 effectively identified significant numbers of B cells in IgHMOG mice but 
only rare cells in wild type C57Bl/6 (Figure 5A). Significantly more MOG-binding B  
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Figure 4: Binding of unlabeled MOGtag protein by MOG-specific B cells. (A) Lymph 
node cells from wild type C57Bl/6 and IgHMOG mice were harvested and stained for 
FACS analysis. B cells (CD19+ CD4-) were analyzed for binding MOGtag using anti-His 
and anti-IgG1-APC secondary and tertiary antibodies, respectively. Representative stains 
are shown. n = 3 mice/group. (B) MOGtag was directly conjugated with Alexa Fluor 647 
using amine-reactive (top) or thiol-reactive reagents. Binding of different titers of labeled 
MOGtag to IgHMOG B cells was assessed by FACS. FMO – Fluorophore minus one (no 
MOGtag). 
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Figure 5: Identification of MOG-specific B cells with MOGtag-A647. (A) Lymph node 
cells from wild type C57Bl/6 and IgHMOG mice were harvested and analyzed for B cells  
(CD19+, CD45R+, CD4-) binding to MOGtag conjugated to A647 using FACS. Symbols 
represent individual mice. ***p<0.001. (B) MOGtag-binding B cell light chain usage. 
Lymph node B cells were analyzed for binding of MOGtag and κ or λ light chain 
antibodies. Representative plots from wild type and IgHMOG mice are shown. n = 3-4. (C) 
Quantification demonstrating enrichment of κ usage in MOGtag-specific B cells from wild 
type and IgHMOG mice. Each symbol represents an individual mouse. *p<0.05. 
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cells expressed κ-light chain compared to the non-specific pool, suggesting that light 
chain usage is an important factor in specificity to MOGtag in both wild type and IgHMOG 
B cells (Figure 5B, C). 
3.4 Effective generation of a T cell-dependent B cell 
germinal center response with MOGtag 
In order to determine if MOGtag is able to activate B cells to initiate a GC, GFP+ IgHMOG 
B cells and RFP+ 2D2 (MOG35-55 TCR transgenic (123)) T cells were isolated and 
transferred to wild type C57Bl/6 recipients. These mice were immunized with MOGtag in 
CFA and draining popliteal LNs were harvested 10 days later. Development of the GC 
response was analyzed by FACS. Significantly greater numbers of CD95hi CD38lo GC B 
cells and CD138+ CD19int PCs were detected in immunized mice compared to 
unimmunized controls (Figure 6A and B). As expected, transferred GFP+ IgHMOG B cells 
contributed to the GC response but, interestingly, remained a minor component as 
compared to recipient-derived GFP- cells. This demonstrates that wild type and not just 
mutant IgHMOG cells are activated by MOGtag. Similarly, endogenous GFP- cells made up 
the majority of PCs. Tfh differentiation in immunized mice was confirmed by PD-1 and 
Bcl-6 expression. Again, both transferred MOG35-55-specific RFP+ 2D2 Tfh cells and 
endogenous wild type RFP- Tfh cells were induced by immunization with MOGtag 
(Figure 6A and B, bottom).  
In a separate experiment, draining LNs were harvested for histological analysis. 
Consistent with FACS findings, 10 days post immunization with MOGtag, IgD- GCs were 
apparent in follicles (Figure 7). Serial sections confirmed the expression of Bcl-6 on B 
cells, a transcriptional repressor that is required for GC B cell differentiation (142). Also 
consistent with FACS findings, transferred GFP+ cells were present in the GC but the 
majority of Bcl-6+ cells were GFP-. RFP+ transferred T cells were also clearly evident in 
the follicle and GC, many of which were also PD-1+, representing Tfh cells. Therefore, 
immunization with MOGtag effectively induced the development of a GC response with 
the participation of both endogenous and transferred antigen-specific T and B cells.  
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Figure 6: FACS analysis of the immune response initiated by MOGtag. GFP+ IgHMOG 
B cells and RFP+ 2D2 (MOG35-55-specific) T cells were transferred to non-fluorescent 
wild type C57Bl/6 recipients. 10 days post immunization with MOGtag in CFA, draining 
popliteal lymph nodes were harvested for analysis. (A) FACS was performed to 
determine the frequency of CD138+ CD19int plasma cells (top row), CD95hi CD38lo GC B 
cells (middle row), and Bcl-6hi PD-1hi Tfh cells (bottom row) in unimmunized (Control) 
or immunized mice. Upstream gating is shown to the left of each row. (B) To specifically 
investigate the development of these cell types in transferred MOG-specific cells, cells 
were first gated on GFP (CD19+ CD138- B cells) or RFP (CD4+ T cells), right column. 
Each symbol represents an individual mouse. **p<0.01, ***p<0.001.   
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Figure 7: Histological analysis of the immune response initiated by MOGtag. GFP+ 
IgHMOG B cells and RFP+ 2D2 (MOG35-55-specific) T cells were transferred to wild type 
C57Bl/6 recipients. 10 days post immunization with MOGtag in CFA, draining popliteal 
lymph nodes were harvested for analysis. Histological staining of lymph nodes from 
immunized mice. A magnified view of the area in the square (center) shows Bcl-6 
expression in the same section, and PD-1 expression by RFP+ MOG-specific T cells in 
the GC in an adjacent section. Representative stain of n = 3 mice. Scale bars represent 
100 µm. 
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3.5 MOGtag and MOG35-55 peptide activate different B cells 
to induce a germinal center response 
To determine if MOG35-55 peptide can also activate B cells to initiate a GC response, we 
transferred fluorescent MOG-specific B and T cells to wild type C57Bl/6 recipients and 
immunized them with equimolar (15 nmol) amounts of MOGtag (500 µg), pure MOG1-125 
(225 µg) generated by TEV protease cleavage (Figure 3B), or commercially-synthesized 
MOG35-55 (40 µg). It should be noted that pure MOG1-125 without the thioredoxin tag was 
highly insoluble, making it difficult to determine the precise amount of soluble and 
precipitated protein. Nevertheless, GC cells were evident after immunization with each of 
the three Ags (Figure 8A, top), with MOGtag being the most potent immunogen. 
Importantly, both MOGtag and pure MOG1-125 induced transferred GFP+ IgHMOG B cells 
to activate and differentiate into GC B cells, while immunization with MOG35-55 had no 
ability to do so (Figure 8A, middle). Further, a significantly greater proportion of GC B 
cells bound MOGtag in MOG1-125-immunized mice, while binding was virtually non-
existent in mice immunized with MOG35-55 (Figure 8A, bottom). Note that GC B cells 
downregulate BCR surface expression, and therefore many antigen-specific cells will not 
be labeled with MOGtag. Further, it should be noted that endogenous MOG on the surface 
of oligodendrocyte is glycosylated, and that it remains possible that the MOG35-55-
induced B cell response targets glycosylated but not unglycosylated MOG. As expected, 
there was no defect in T cell activation as measured by CD62L down-regulation, 
including transferred pathogenic RFP+ 2D2 MOG35-55-specific T cells (Figure 8B). 
Together, these experiments demonstrate that while MOG35-55 can induce a GC response, 
pathogenic IgHMOG B cells specific for MOG protein do not participate, nor do wild type 
endogenous cells capable of binding MOGtag.  
3.6 Characterization of MOGtag-induced EAE 
The above experiments confirm that immunization with MOGtag results in the initiation 
of an immune response that incorporates appropriate recognition of mouse MOG protein 
by both T and B cells. To determine if immunization also induces disease, wild type 
C57Bl/6 mice were immunized once and administered PTX i.p. at the time of 
immunization and again 2 days later. Due to a past report of relatively low disease  
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Figure 8: MOGtag, MOG1-125, and MOG35-55 induce GC responses, but MOG35-55 
does not activate pathogenic B cells that bind MOG protein. GFP+ IgHMOG B cells and 
RFP+ 2D2 T cells were transferred to wild type C57Bl/6 recipients that were then 
immunized with equimolar amounts of MOGtag, pure MOG1-125, or MOG35-55 in CFA. 
Draining popliteal lymph nodes were analyzed by FACS 10 days later for (A) GC B cell 
(CD95hi CD38lo) development and (B) activation of T cells, as defined by 
downregulation of CD62L (shown as CD62Llo). Percent of the indicated population for 
the relevant parent (A: B cells – top, GC B cells – middle and bottom, B: all T cells – top, 
transferred RFP+ T cells – bottom) is shown. Each symbol represents an individual 
mouse. Multiple groups were compared using one-way ANOVA followed by a post-hoc 
Tukey’s test.   *p<0.05, **p<0.01.
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incidence following immunization with a different fusion protein containing mouse 
MOG1-125 (143), we also included mice with enriched numbers of MOG-specific immune 
cells, including wild type recipients of transferred IgHMOG B cells and 2D2 T cells, as 
well as mice with enhanced endogenous MOG reactivity in the B cell compartment 
(IgHMOG +/+) or in both the B and T compartments (IgHMOG +/-  2D2+/-). Surprisingly, all 
groups developed severe disease with high incidence (Figure 9). There was no difference 
in disease severity between wild type and groups with endogenously enhanced MOG 
reactivity, although disease emerged earlier and was more severe in mice that had 
received transferred MOG-reactive T and B cells. No evidence of recovery was observed 
in any group.  
In a separate experiment, wild type mice were immunized with MOGtag as described 
above with the exception that only one dose of PTX was administered to limit disease 
severity. Similar to our initial experiment, 10 of the 11 mice developed disease within 10 
days of immunization (Figure 10A). Mice were sacrificed 23 days post-immunization (~2 
weeks post onset of signs of disease). FACS analysis of inguinal draining LNs revealed 
an ongoing GC response at this late timepoint (Figure 10B), demonstrating an ongoing 
source for autoreactive T and B cells to drive chronic disease. Interestingly, the single 
mouse that did not develop overt signs of disease nevertheless had a GC response similar 
to that of mice that did develop disease. 
Spinal cords were collected from the above mice and prepared for immunofluorescence 
analysis of cellular infiltrates and demyelination. Sections were taken from 7 to 9 evenly 
spaced sites spanning the cervical to lumbar regions of the spinal cord. Meningeal 
infiltration by CD4+ and CD45R+ cells (T cells and B cells, respectively) and CD4+ 
infiltration of the white matter was evident in all mice that developed overt signs of 
disease (10/11 immunized mice) (Figure 11). No evidence of immune cells was observed 
in the single mouse that did not develop disease or in the three unimmunized mice. 
Clusters of B cells in the meninges were evident in all diseased mice, but only very rarely 
deeper in the spinal cord tissue. Clusters varied considerably in size from 5 to 20 cells 
(Figure 11i, iii) to much larger (Figure 11ii, vi). Similar to observations in human MS 
patients (144), these clusters were sometimes closely associated with white matter  
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Figure 9: Characterization of MOGtag-induced EAE. EAE development in wild type 
mice and in mice with enhanced immune responsiveness to MOG. Different strains of 
mice, including wild type C57Bl/6 mice, wild type recipients of MOG-specific T and B 
cells (A.T.), IgHMOG, and 2D2+/- IgHMOG mice, were immunized with MOGtag in CFA. 
PTX was administered at the time of immunization and again 2 days later. Mice were 
monitored and disease severity was scored. Scores are shown only for mice that 
developed signs of disease. Incidence for each strain is shown in the legend. Graph shows 
mean +/- SEM. n = 3-6. *p<0.05 vs C57Bl/6. 
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Figure 10: FACS analysis of MOGtag-induced EAE. (A) EAE was induced with 
immunization with MOGtag in CFA and administered one dose of PTX at the time of 
immunization. Mice were monitored for signs of disease. Scores are shown only for mice 
that developed signs of disease. Incidence is shown in the legend. Graph shows mean +/- 
SEM. (B) Mice were sacrificed 23 days post immunization and the presence of GC B 
cells in draining inguinal lymph nodes was analyzed by FACs. (Left) Representative 
plots from unimmunized and MOGtag-immunized C57Bl/6 mice and (right) quantification 
of GC (CD95hi CD38lo) B cells in mice are shown. Each symbol represents an individual 
mouse. Note that the open square represents the individual mouse that did not develop 
signs of disease. **p<0.01. 
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Figure 11: Histological analysis of MOGtag-induced EAE. Spinal cords were collected 
and prepared for histology. 7-9 evenly spaced segments were prepared for each spinal 
cord, spanning the cervical to lumbar regions. Representative images from MOGtag 
immunized mice showing common patterns of demyelination and T cell (CD4+) and B 
cell (CD45R+) infiltration. Representative of n = 10 diseased mice. * - region of white 
matter demyelination, open arrow – B cell meningeal clusters, closed arrow – T cell grey 
matter infiltrates, g – grey matter, w – white matter. Scale bars represent 200 µm. 
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infiltration by T cells (Figure 11iii, vi). While loss of myelin was typically associated 
with extensive T cell invasion and was observed in 7/10 diseased mice (Figure 11iii, iv, 
vi), it was not always associated with B cell clusters (Figure 11iv). Importantly, recent 
reports from human MS patients have noted inflammatory lesions in the gray matter 
(145). CD4+ T cells were apparent in the gray matter of 8/10 diseased mice, often only as 
diffuse cells within the tissue (Figure 11iii), but sometimes as distinct clusters of invading 
cells (Figure 11v) or as an apparent continuation of extensive white matter infiltration 
(Figure 11vi). Blinded evaluation of the tissue sections revealed that T and B cell 
infiltration was evenly distributed throughout the spinal cord (Figure 12). The average 
number of clusters per section correlated with disease severity, while infiltration by CD4+ 
T cells did not (Figure 13). Taken together, MOGtag is a potent immunogen capable of 
inducing EAE characterized by ongoing GC responses and autoimmune CNS pathology 
features similar to human MS. 
3.7 Comparison of EAE induced by MOGtag, MOG1-125, and 
MOG35-55 
A separate experiment was performed comparing EAE induced by MOGtag, pure MOG1-
125, and MOG35-55. Separate groups of wild type C57Bl/6 mice were immunized with 
equimolar (15 nmol) amounts of the given Ag in CFA and administered one dose of PTX 
at the time of immunization. Although signs of disease appeared most rapidly in MOGtag-
immunized mice, all mice eventually showed signs of disease (Figure 14A). There was 
no difference in disease severity between the groups (Figure 15A). Consistent with 
above, at the end of the experiment (22 days post-immunization) ongoing GC responses 
were observed in mice immunized with MOGtag (Figure 15B). Interestingly, the GC 
response was significantly greater in these mice compared to mice immunized with either 
pure MOG1-125 or MOG35-55. Further, MOGtag binding by GC B cells was significantly 
greater in MOGtag-immunized mice and almost non-existent in MOG35-55-immunized 
mice (Figure 14B), consistent with our findings of MOGtag binding by B cells activated 
by MOG protein and peptide (Figure 8).  
Histological analysis of spinal cord sections again revealed extensive CD4+ T cell 
infiltration in the meninges and white matter of the majority of MOGtag-immunized mice.  
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Figure 12: Quantification of B and T cell infiltration in MOGtag-induced CNS 
pathology. Spinal cords were collected and prepared for histology. 7-9 evenly spaced 
segments were prepared for each spinal cord, spanning the cervical to lumbar regions. 
CD4+ T cell infiltration of the white and grey matter was scored separately (0 – no cells, 
1 – diffuse infiltration, 2 – severe infiltration) and CD45R+ B cell clusters were counted 
for each section for each mouse by a blinded reviewer. 
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Figure 13: Correlation of immune cell infiltration in the CNS and MOGtag-induced 
EAE disease score. (A) The average number of B cell clusters counted per spinal cord 
section analyzed compared to the cumulative disease score for each mouse. (B) The sum 
CD4+ cell infiltration score of the white and grey matter (0 – no cells, 1 – diffuse 
infiltration, 2 – severe infiltration) of all spinal cord sections compared to the cumulative 
disease score for each mouse. Each point represents an individual mouse. 
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Figure 14: EAE induction by MOGtag, pure MOG1-125, and MOG35-55 peptide. (A) 
Disease incidence and onset in C57Bl/6 mice immunized with equimolar amounts of 
MOGtag, pure MOG1-125, or MOG35-55 peptide. (B) MOGtag binding by GC B cells from 
draining lymph nodes of MOGtag and MOG35-55 EAE mice. Each symbol represents an 
individual mouse. **p<0.01. (C) Uncommon severe CD4+ T cell infiltration into white 
matter of spinal cord, as observed in one MOG35-55-induced EAE mouse. 
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Figure 15: FACs analysis of EAE induced by MOGtag, pure MOG1-125, and MOG35-55 
peptide. (A) EAE was induced in wild type C57Bl/6 mice via immunization with 
equimolar amounts of MOGtag, pure MOG1-125, or MOG35-55 peptide in CFA and 
administered one dose of PTX at the time of immunization. Disease incidence is 
indicated in the legend. Graph shows mean +/- SEM. (B) Mice were sacrificed 22 days 
post-immunization and draining inguinal lymph nodes were analyzed by FACS for the 
ongoing presence of CD95hi CD38lo GC B cells in unimmunized (Control) and 
immunized mice. Each symbol represents an individual mouse. Multiple groups were 
compared using one-way ANOVA followed by a post-hoc Tukey’s test. *p<0.05, 
***p<0.001. 
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B cell clusters in the meninges were evident in 4/6 mice (Figure 16). More variable 
patterns of inflammation, ranging from diffuse to more severe, were observed in MOG35-
55-immunized mice, and B cell cluster formation was only prevalent in 2/6 mice in the 
group (Figure 16). Demyelination was also less extensive, with the exception of one 
mouse that had massive white matter infiltration by both CD4+ T cells and CD45R+ B 
cells (Figure 14C). Surprisingly, this mouse was the last to show overt signs of disease at 
20 days post-immunization and had by far the lowest cumulative score of all mice in the 
experiment (3, as compared to the group average of 16.6). Therefore, as with human MS 
patients, outward physical disability is not always a reliable measure of underlying 
pathology. Further, these findings demonstrate that B cell clusters can form 
independently of B cell binding of endogenous autoantigen.  
3.8 MOGtag-induced EAE in the absence of B cell 
recognition of antigen  
Finally, to determine the contribution of anti-myelin B cells to MOGtag-induced EAE 
pathology, we immunized wild type C57Bl/6 and B1-8 Jκ-/- mice with MOGtag in CFA 
followed by one dose of PTX, and followed disease development. B1-8 mice possess a 
heavy chain knockin that, when paired with an appropriate lambda light chain, confers 
specificity for the hapten nitrophenol (NP) (135), an irrelevant foreign Ag. The deletion 
of the kappa light chain (Jκ-/-) results in >95% B cell specificity for NP in these mice 
(136), eliminating the endogenous B cell response to MOG while maintaining otherwise 
relatively normal B cell populations and lymphoid tissue development.  
Consistent with previous studies showing that EAE induced by rodent MOG proteins is B 
cell independent (125, 130, 131), most (4/5) B1-8 Jκ-/- mice developed disease that was 
initially indistinguishable from that in wild type mice (Figure 17A). Following the acute 
phase, however, disease score was significantly lower in B1-8 Jκ-/- mice, perhaps 
indicating that B cells contribute to processes later in disease. FACS analysis of LNs at 
22 days post-immunization revealed that while ongoing GC responses were again evident 
in wild type mice, they were essentially absent in B1-8 Jκ-/- mice (Figure 17B). B cell 
binding of MOGtag was also completely absent in B1-8 Jκ-/- mice compared to wild type  
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Figure 16: Histological analysis of EAE induced by MOGtag, pure MOG1-125, and 
MOG35-55 peptide. EAE was induced in C57Bl/6 mice via immunization with equimolar 
amounts of MOGtag, pure MOG1-125, and MOG35-55 peptide. Representative images of 
spinal cords from EAE mice induced with MOGtag (i, ii) (n = 6) or MOG35-55 (iii, iv) (n = 
6) showing common patterns of pathology. * - region of white matter demyelination, 
open arrow – B cell meningeal clusters, g – grey matter, w – white matter. Scale bars 
represent 200 µm. 
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Figure 17: MOGtag-induced EAE in C57Bl/6 and B1-8 Jκ -/- mice. (A) EAE was 
induced in C57Bl/6 or B1-8 Jκ-/- mice via immunization with MOGtag. Disease incidence 
is indicated in the legend. Scores are shown only for mice that developed signs of 
disease. Graph shows mean +/- SEM. (B) Mice were sacrificed 22 days post 
immunization and draining inguinal lymph nodes were analyzed by FACS for the 
ongoing presence of CD95hi CD38lo GC B cells in unimmunized (Control) and 
immunized mice. Each symbol represents an individual mouse. Multiple groups were 
compared using one-way ANOVA followed by a post-hoc Tukey’s test. *p<0.05. 
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mice, as expected (Figure 18A). In contrast, there was no reduction in CD4+ T cell 
activation, consistent with the elimination of the anti-MOG B cell response but a largely 
normal T cell response in these mice (Figure 18B). 
Histological analysis of spinal cord sections revealed that CD4+ T cell infiltration in the 
meninges and white matter was often closely associated with regions of demyelination in 
both wild type and B1-8 Jκ-/- groups (Figure 19). However, demyelination was less 
extensive in B1-8 Jκ-/- mice. Similarly, while meningeal B cell clusters were consistently 
observed in diseased wild type mice, they were less common and tended to be 
considerably smaller in B1-8 Jκ-/- mice. Altogether, these findings suggest that B cells 
can infiltrate the CNS and form clusters independently of their ability to recognize the 
endogenous autoantigen.  
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Figure 18: MOGtag-induced EAE in C57Bl/6 and B1-8 Jκ -/- mice. EAE was induced in 
C57Bl/6 or B1-8 Jκ-/- mice via immunization with MOGtag  in CFA and administered one 
dose of PTX. Mice were sacrificed 22 days post immunization and draining inguinal 
lymph nodes of unimmunized (Control) and immunized mice were analyzed by FACS. 
(A) CD95hi CD38lo GC B were analyzed for binding of MOGtag. (B) Activation of CD3+ 
CD4+ T cells was determined by their downregulation of CD62L. Each symbol represents 
an individual mouse. Multiple groups were compared using one-way ANOVA followed 
by a post-hoc Tukey’s test. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 19: Histological analysis of MOGtag-induced EAE in C57Bl/6 and B1-8 Jκ -/- 
mice. EAE was induced in C57Bl/6 or B1-8 Jκ-/- mice via immunization with MOGtag. 
Representative images of spinal cords from C57Bl/6 (i, ii) (n=5) or B1-8 Jκ-/- (iii, iv) 
(n=4) EAE mice showing common patterns of pathology. * - region of white matter 
demyelination, open arrow – B cell meningeal clusters, g – grey matter, w – white matter. 
Scale bars represent 200 µm. 
 
46 
 
Chapter 4  
4 Discussion 
In this study we developed a new fusion protein (MOGtag) containing the extracellular 
domain of mouse MOG for the purpose of inducing a CNS autoimmune response. Our 
system allows for the simple purification of large quantities of protein using common 
laboratory equipment. We characterized the T cell and B cell immune response that 
MOGtag initiates and confirm the contribution of B cells to pathology in this model of 
CNS autoimmunity. Interestingly, we report that B cell recognition of the endogenous Ag 
was not a requirement for infiltration and retention in the CNS. 
4.1 Advantages of the MOGtag system  
While other similar protein Ags are available, our protein system has several advantages 
that we hope will facilitate its wider adoption in the EAE field. The hydrophobic 
properties of MOG makes it highly insoluble and difficult to purify in large quantities. To 
improve the solubility and facilitate purification of MOG, we fused mouse MOG1-125 to a 
tag containing thioredoxin (141). Indeed, while some MOG fusion proteins have adapted 
similar approaches to counteract this issue, these systems are based on human MOG 
(134). To our knowledge, we have not identified a fusion protein based on mouse MOG 
using a similar system to ours. Additionally, other MOG fusion proteins that we 
inspected contain tags for purification and, in some cases, additional sequences that we 
were not able to identify. Unique to MOGtag, the entire extraneous tag can be removed by 
cleavage with TEV protease, leaving only pure MOG1-125. As expected, this reduces 
solubility and this may in part explain its lower immunogenicity compared to MOGtag. 
Alternatively, it is possible that the presence of the foreign thioredoxin domain in MOGtag 
may help to overcome tolerance mechanisms. Nevertheless, pure MOG1-125 remained 
capable of inducing an anti-MOG response and EAE. To further facilitate its production, 
we codon optimized and used a more efficient T7 (146) expression system that resulted in 
the production of large amounts of protein from relatively small culture volumes. Here 
we describe a simple centrifugation based method of purification that can be performed 
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in virtually any laboratory with basic equipment. Indeed, while protein purification was 
the primary factor limiting the amount of protein that we could produce, we acknowledge 
that HPLC or other specialized protein handling equipment may improve yield.  
4.2 Protein versus peptide antigens in modeling B and T 
cell germinal center interactions 
The initiation of a GC response is dependent on B and T cell interactions for the same 
cognate Ag – a phenomenon that is evident in immune responses against whole proteins. 
Here we confirm appropriate recognition of MOGtag fusion protein by MOG-specific 
IgHMOG B cells, and the induction of a GC response upon immunization with MOGtag in 
CFA. Activation of MOG-specific IgHMOG B cells is of particular relevance to this model 
as these cells have been confirmed to contribute to autoimmune pathology (120, 121). In 
similar studies using a model foreign Ag system (NP-haptinated ovalbumin), transferred 
pre-rearranged antigen-specific B cells dominated the GC response (139). Interestingly, 
the contribution of transferred MOG-specific B cells to the GC was much more limited. 
Since MOG1-125 was fused to a thioredoxin tag, it was possible that endogenous B cells 
recognizing the foreign tag were outcompeting autoreactive MOG-specific B cells. 
However this was not the case as mice immunized with pure MOG1-125 also had a 
similarly low autoimmune GC response. It is not clear why endogenous B cells would 
dominate the anti-MOG GC response in the presence of elevated numbers of transferred 
cells with predetermined Ag specificity. A study by Dal Porto et al. demonstrated that 
higher affinity B cells can exclude cells with fixed lower affinity from the GC (147). This 
does not seem to be the case as the IgHMOG mutation is derived from a hybridoma 
selected for its ability to bind MOG and has the mutant variable gene inserted at the 
endogenous locus (124), thereby allowing for appropriate somatic hypermutation and 
affinity maturation to occur. Further studies are required to investigate the differences in 
GC development following immunization with foreign Ag and autoantigen. 
Immunization with MOG35-55 peptide was also capable of inducing a GC response, 
although not as well as immunization with MOGtag. This was interesting as Ag 
presentation by B cells is normally limited to conformational Ags that bind the Ag-
specific BCR. Nevertheless, short linear peptide Ags can also bind the BCR. 
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Furthermore, peptide Ags can also load directly onto MHC II, bypassing BCR 
recognition and intracellular processing (148). Therefore activated B cells may present 
peptides independent of their BCR specificity. More importantly, the GC response 
initiated by MOG35-55 did not activate nor incorporate participation of MOG-binding or 
pathogenic IgHMOG B cells, consistent with the idea that short peptides cannot model a 
response incorporating both T and B cell recognition of protein.  
The majority of EAE studies have analyzed B cell responses primarily in the context of 
Ab production (111, 112). However human studies of CD20 B cell-depleting therapies 
indicate that the primary pathogenic mechanism of B cells in MS is not through the 
production of these Abs (102). There is a growing body of evidence suggesting that GC-
derived autoreactive B cells contribute to pathology. We are unaware of a prior 
description of the GC response, and therefore are the first group to characterize such a 
response in EAE induced with mouse MOG35-55 peptide and MOG1-125 protein.  Therefore 
we believe EAE models induced with protein Ags like MOGtag may be more appropriate 
to investigate these pathological mechanisms. 
4.3 MOGtag-induced EAE features autoimmune CNS 
pathology similar to human MS 
Immunization with MOGtag resulted in a monophasic EAE disease with little evidence of 
recovery. The ongoing GC response and clear evidence of active inflammation in the 
spinal cords of EAE mice confirms the chronic nature of disease. The CNS pathology in 
EAE induced with MOGtag, as we describe here, has important features that are otherwise 
absent, or overlooked in some peptide EAE models. The observation of immune cell 
infiltrates in gray matter of some mice is of particular relevance to increasing reports of 
gray matter pathology in human MS patients (83). In contrast, inflammatory infiltrates 
are usually restricted to the white matter in other EAE models. Also of importance are the 
meningeal B cell clusters that were often found in association with demyelinating lesions 
in MOGtag-immunized mice. These structures are reminiscent of so-called tertiary 
lymphoid tissues that have been reported in human MS and are often associated with 
more severe disease (89, 149).  
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An additional advantage of the use of larger protein Ag such as MOGtag to induce EAE is 
that its utility is not limited to specific strains, unlike short peptides mimicking MHC-
restricted T cell epitopes. These highly reduced models were developed shortly after the 
mechanisms of antigen-recognition by T cells were discovered and great effort was 
expended to map T cell epitopes. Very few contemporary EAE studies benefit from such 
highly reduced models. Therefore MOGtag-induced EAE may be a useful model to 
investigate the role of B cells and these clusters in the pathology of autoimmune-driven 
inflammation of the CNS.  
4.4 B cells contribute to ongoing CNS pathology in MOGtag-
induced EAE 
While we did not observe a significant difference in disease score between MOGtag- and 
MOG35-55-induced EAE, this in part could be attributed to the lack of sensitivity of the 
EAE grading scale. The overall histopathology in the spinal cord tended to be more 
severe in MOGtag-immunized mice, with evidence of more immune cell infiltration and 
demyelination. While this could simply be a function of a larger immune response 
induced by MOGtag, it seems unlikely as equimolar amounts of protein and peptide Ag 
were used for inducing EAE. Regardless, it is possible that multiple immunizations with 
MOG35-55 or increasing its concentration could result in equal pathology. Alternatively, 
the differences may be the result of a more complex immune response that incorporates B 
cell targeting of Ag, as we demonstrate here, or potentially CD8+ T cells as well.  
The role of B cells in EAE has long been controversial with conflicting views within the 
field. It is well established that CD4+ T cells alone are sufficient to mediate the CNS 
autoimmune response. B cells are not required for EAE induced with either short peptides 
or protein Ags based on rodent MOG. However as demonstrated in our studies, the 
reduced CNS pathology in B1-8 Jκ-/- mice suggests that B cell mechanisms do contribute 
to ongoing pathology in this model of MOGtag-induced EAE. Additionally, we were 
surprised to find similar meningeal B cell clusters in some mice immunized with MOG35-
55 peptide, suggesting that B cell recognition of autoantigen may not be a prerequisite for 
cluster formation. Further investigation will be required to rule out a contribution from B 
cells that recognize the glycosylated form of endogenous MOG, as lack of binding to 
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unglycosylated MOGtag does not exclude this possibility. Nevertheless, small meningeal 
B cell clusters were also evident in some B1-8 Jκ-/- mice that, because of the absence of 
kappa light chain and expression of a heavy chain directed towards an irrelevant Ag, 
almost certainly has no capacity to recognize any form of MOG. 
Ab contribution to pathology was not analyzed in this particular study, however their role 
in disease has been described in the field of EAE. Transfer of autoantibodies against 
MOG was reported to contribute to demyelination and exacerbate disease in rats, mice 
and primates with EAE (127, 150, 151). Of particular importance is that the pathogenic 
ability of Abs is dependent on the type of MOG used. In a comparative study performed 
by Marta et al., mice immunized with rodent-based protein Ags produced Abs that did 
not bind glycosylated endogenous MOG nor contribute to pathology (152). Interestingly, 
the Ab response induced by human MOG in mice was demonstrated to cross-react with 
the glycosylated endogenous Ag on the surface of oligodendrocytes, despite the fact that 
the bacterially-produced Ag is not glycosylated itself (152). We do not consider MOGtag 
protein to be drastically different from currently available protein Ags. Therefore it is 
possible that the Abs generated in MOGtag-induced EAE contribute limited pathology due 
to an inability to recognize the glycosylated endogenous Ag. Further investigation is 
necessary to determine the role and Ag-specificity of autoantibodies in this model of 
CNS autoimmunity.   
4.5 Significance 
MS is a heterogeneous and complex autoimmune disease in part complicated by the 
multitude of immune cell players. While MS was originally thought to be T cell-
mediated, recent clinical studies have shed light on the importance of B cells in 
contributing to ongoing pivotal pathogenic processes in this disease. Prior to this 
discovery the role of B cells in MS were largely overlooked, and consequently poorly 
understood. This was in part due to highly reduced peptide models of EAE which, as we 
demonstrate here in our study, are not appropriate models for studying the role of B cells 
in the ongoing immune response and CNS pathology.  
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Although EAE studies have improved our knowledge of CNS inflammation, these highly 
reduced peptide models have inevitably shortsighted our understanding of the complex 
immune response in MS. There is a clear need for alternatives to short-peptide induced 
models of EAE that better reflect the complexity and other features of human MS. We 
show here that MOGtag induces a more complex immune response and consistent CNS 
autoimmunity. Importantly, the involvement of pathogenic B cells in this model of EAE 
provides the critical foundation for which to study the development, recruitment and 
pathogenic processes of B cells to ongoing disease. Further combined with its expression 
efficiency and relatively simple purification protocol, MOGtag becomes an attractive 
candidate for more general use in the EAE field. By making a MOG protein autoantigen 
more accessible, we hope that this model of CNS autoimmunity can begin to regain 
dominance from minimalist peptide-induced models.  
4.6 Future directions 
The goal of this study was to develop a myelin protein Ag appropriate for studying 
pathogenic B cell responses in a model of CNS autoimmunity. Of particular importance 
to the emerging B cell field in EAE is the presence of meningeal B cell clusters, 
indicating that B cells are recruited and retained in the inflamed CNS in this model. Thus 
future studies are required to characterize the B cell phenotypes within the meningeal 
clusters and to elucidate their potential role in CNS autoimmune disease pathogenesis. 
FACS and histological studies will be performed on spinal cord tissues to identify if B 
cells found within the inflamed CNS represent PCs (CD138+), Ag-experienced memory 
B cells (PD-L2, CD80, CD73) or naïve-like follicular B cells (IgD+, IgM+). More 
importantly, these studies will determine if meningeal B cell clusters represent tertiary 
lymphoid structures capable of initiating germinal centers (as determined by Bcl6+ 
expression on B and T cells and the presence of CD35+ follicular dendritic cells) as 
suggested by some studies of human MS. Furthermore, additional ELISPOT and ELISA 
assays will be performed and compared to disease in order to examine the contribution of 
Abs to CNS pathology in the MOGtag-induced EAE model. 
In this study we demonstrate that B cells are recruited to the CNS independent of their 
Ag-specificity. Thus it is of interest for future studies to elucidate the Ag-specificity of 
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the B cells in order to determine if disease progression is facilitated through direct 
targeting of the autoAg or non-specifically via other mechanisms. Based on the methods 
used in this thesis, we did not completely rule out the contribution from B cells that 
recognize the glycosylated form of endogenous MOG. Therefore future studies will be 
performed to adapt our MOGtag vector for expression in a eukaryotic insect cell line for 
the purpose of producing glycosylated mouse MOG protein.  
At the moment, the mechanisms of B cell recruitment into the inflamed CNS are not well 
understood. While the therapeutic effects of Natalizumab (anti-α4-integrin) has been 
mainly attributed to the blocking of T cells, it is possible that it also functions by 
preventing the entry of B cells into the CNS. Therefore future studies involving an 
adoptive transfer of activated B cells, followed by the administration of anti-α4-integrin 
and/or anti-P-selectin blocking Abs will be performed to identify the adhesion molecules 
involved in B cell trafficking into the inflamed CNS.  
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